EA201890447A1 - Гуманизированные антитела к рецептору ccr7 - Google Patents

Гуманизированные антитела к рецептору ccr7

Info

Publication number
EA201890447A1
EA201890447A1 EA201890447A EA201890447A EA201890447A1 EA 201890447 A1 EA201890447 A1 EA 201890447A1 EA 201890447 A EA201890447 A EA 201890447A EA 201890447 A EA201890447 A EA 201890447A EA 201890447 A1 EA201890447 A1 EA 201890447A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
conditions
receptor
ccr7
cdr
Prior art date
Application number
EA201890447A
Other languages
English (en)
Other versions
EA037397B1 (ru
Inventor
Яп Виллем Бак
Роналд Босхейзен
Ваутер Корнелис Пейк
Йохан Тюркстра
Original Assignee
Пепмаб Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пепмаб Б.В. filed Critical Пепмаб Б.В.
Publication of EA201890447A1 publication Critical patent/EA201890447A1/ru
Publication of EA037397B1 publication Critical patent/EA037397B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)

Abstract

Настоящее изобретение относится к гуманизированным анти-CCR7-антителам и композициям, содержащим такие антитела. Антитела и композиции пригодны для лечения злокачественного новообразования, опухолевые клетки которого экспрессируют рецептор CCR7, в лечении воспалительных состояний, состояний или осложнений, возникающих в результате трансплантации тканей или органов, и состояний или осложнений, возникающих в результате или связанных с фиброзом. Получены детальные экспериментальные данные для нескольких антител, полученных из мышиных антител. Мышиное антитело с внутренним названием mAb729 [имеющее в качестве CDR VH1:GLTFRDFA; VH2:ISSGGFYT; VH3:VRRAYRYDGTGDYSALDY; VL1:QDIGPS; VL2:ATS; VL3:LQYASSPLT] дополнительно гуманизировано (внутреннее название mAb 650_H 1L1). Указанное антитело ингибирует интернализацию рецептора CDR, как показано экспериментальными данными.
EA201890447A 2015-08-10 2016-08-10 Гуманизированные антитела к рецептору ccr7 EA037397B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180415 2015-08-10
PCT/EP2016/069055 WO2017025569A1 (en) 2015-08-10 2016-08-10 Humanized anti-ccr7 receptor antibodies

Publications (2)

Publication Number Publication Date
EA201890447A1 true EA201890447A1 (ru) 2018-11-30
EA037397B1 EA037397B1 (ru) 2021-03-24

Family

ID=53836447

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890447A EA037397B1 (ru) 2015-08-10 2016-08-10 Гуманизированные антитела к рецептору ccr7

Country Status (17)

Country Link
US (3) US10640565B2 (ru)
EP (1) EP3334457B1 (ru)
JP (1) JP6844864B2 (ru)
KR (1) KR102663440B1 (ru)
CN (1) CN109069620B (ru)
AU (1) AU2016305283B2 (ru)
BR (1) BR112018002877A2 (ru)
CA (1) CA2994214C (ru)
DK (1) DK3334457T3 (ru)
EA (1) EA037397B1 (ru)
ES (1) ES2828368T3 (ru)
HU (1) HUE051920T2 (ru)
IL (1) IL257359B (ru)
MX (1) MX2018001596A (ru)
PT (1) PT3334457T (ru)
SI (1) SI3334457T1 (ru)
WO (1) WO2017025569A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994214C (en) * 2015-08-10 2024-03-12 Pepmab B.V. Humanized anti-ccr7 receptor antibodies
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
EP3898688A1 (en) * 2018-12-18 2021-10-27 Catapult Therapeutics B.V. The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
BR112022006632A2 (pt) * 2019-10-09 2022-06-28 Catapult Therapeutics B V Uso de um anticorpo anti-ccr7 em terapias de combinação com um inibidor de btk e/ou inibidor de bcl2 para tratamento de malignidades hematológicas
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
CN112957472B (zh) * 2021-02-05 2021-11-16 无锡市第五人民医院 靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR20230161759A (ko) * 2022-05-19 2023-11-28 국민대학교산학협력단 Ccr7의 활성 조절 항체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2007003216A1 (en) 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US8865170B2 (en) 2010-09-28 2014-10-21 Sekisui Chemical Co., Ltd. Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
WO2013184200A1 (en) * 2012-06-05 2013-12-12 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr7
WO2014151834A2 (en) 2013-03-15 2014-09-25 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
CA2994214C (en) * 2015-08-10 2024-03-12 Pepmab B.V. Humanized anti-ccr7 receptor antibodies

Also Published As

Publication number Publication date
HUE051920T2 (hu) 2021-03-29
CA2994214A1 (en) 2017-02-16
WO2017025569A1 (en) 2017-02-16
KR102663440B1 (ko) 2024-05-07
BR112018002877A2 (pt) 2018-11-06
PT3334457T (pt) 2020-09-24
JP6844864B2 (ja) 2021-03-17
JP2018522568A (ja) 2018-08-16
US10640565B2 (en) 2020-05-05
AU2016305283B2 (en) 2022-05-26
EP3334457A1 (en) 2018-06-20
EA037397B1 (ru) 2021-03-24
IL257359A (en) 2018-04-30
CN109069620B (zh) 2022-04-26
AU2016305283A1 (en) 2018-02-22
US20220135693A1 (en) 2022-05-05
KR20180030931A (ko) 2018-03-26
CA2994214C (en) 2024-03-12
EP3334457B1 (en) 2020-08-26
MX2018001596A (es) 2018-05-02
ES2828368T3 (es) 2021-05-26
DK3334457T3 (da) 2020-09-21
US20200362043A1 (en) 2020-11-19
CN109069620A (zh) 2018-12-21
IL257359B (en) 2022-03-01
US11254749B2 (en) 2022-02-22
US20180237529A1 (en) 2018-08-23
SI3334457T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
EA201890447A1 (ru) Гуманизированные антитела к рецептору ccr7
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201991099A1 (ru) Антитела против cd73 и их применение
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
EA202091747A1 (ru) Составы антитела b7-h4
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA202190807A1 (ru) Антитела к синуклеину
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.